Reference Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Ref Type Abstract
PMID
Authors Hongyun Zhao; Yanqiu Zhao; Yuxiang Ma; Yan Zhang; Zhangzhou Huang; Ying Cheng; Zhengbo Song; Yongzhong Luo; Juan Li; Wei Wei; Yaling Qi; Binyan Xia; Yuexia Zeng; Jing Lv; Li Zhang
Title Abstract CT052: A highly selective, brain-penetrant and overcoming G2032R resistance ROS1 inhibitor JYP0322 in NSCLC patients with ROS1 fusion
Journal Vol Issue Date Pages Journal Short Title
Cancer Research 85 8_Supplement_2 April 25 2025 Cancer Res
URL https://aacrjournals.org/cancerres/article/85/8_Supplement_2/CT052/761656/Abstract-CT052-A-highly-selective-brain-penetrant
Abstract Text JYP0322 is a potent, brain-penetrant and highly selective ROS1 inhibitor, demonstrating over 100-fold selectivity for ROS1 compared to TRKA and sub-nanomolar potency against the ROS1 G2032R resistance mutation. JYP0322 is designed to simultaneously address the key clinical challenges including ROS1 resistance mutations, tumor brain metastases while avoiding the off-target neurotoxicity associated with TRK inhibition. Method: The Phase I study (NCT06128148) was designed to evaluate safety, pharmacokinetics (PK), and preliminary clinical efficacy in patients with locally advanced or metastatic ROS1+NSCLC, including both ROS1 TKI pre-treated patients as well as TKI naïve patients. Response was assessed by investigators according to RECIST V1.1. Results: As of December 10, 2024, dose escalation study was conducted across 7 dose levels: 50mg qd, 100mg qd, 200mg qd, 100mg bid, 150mg bid, 200mg bid, 150mg tid and dose expansion stage is ongoing at doses of 100mg bid, 150mg bid and 150mg tid. A total of 73 NSCLC patients were enrolled. No dose-limiting toxicities were observed. The most frequently reported treatment related adverse events (TRAE) were low grade including weight gains (32.9%), hyperglyceridemia (31.5%), hypercholesteremia (26%), and AST elevation (21.9%). Grade 3-5 TRAE occurred in 12.3% patients. Only low grade neurotoxicities (6.8%) occurred. Among 58 efficacy evaluable patients, objective response rates (ORRs) were 85.7% (12/14) for ROS1 TKI naive, 54.5% (12/22) for patients previously received ≥2L systemic therapy and ≥1 prior ROS1 TKIs including 19 patients pre-treated with 2 to 4 ROS1 TKIs (Table). In ROS1 G2032R mutant cancers, ORR was 71.4% (5/7) with 3 patients pre-treated with Lorlatinib. In patients with measurable brain metastasis at baseline, intracranial ORR was 33.3% (2/6) and intracranial DCR was 83.3%. JYP0322 showed significantly brain penetration ability with the brain to plasma ration 1.20. Enrollment in the dose expansion stage is ongoing. Conclusions: JYP0322 had a favorable safety profile with a low incidence of neurotoxicities. It showed highly promising anti-tumor effects in patients with ROS1+NSCLC including both TKI-naïve and TKI pre-treated patients, as well as those with TKI-heavily treated, brain metastases, or harboring ROS1 G2032R mutation.

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
JYP0322 JYP0322 2 0
Drug Name Trade Name Synonyms Drug Classes Drug Description
JYP0322 JYP-0322|JYP 0322 ROS1 Inhibitor 23 JYP0322 selectively inhibits ROS1, with activity against ROS1 G2032R, which potentially leads to decreased proliferation of ROS1-positive tumor cells (Cancer Res (2025) 85 (8_Supplement_2): CT052, NCI Drug Dictionary).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ROS1 fusion ROS1 G2032R lung non-small cell carcinoma predicted - sensitive JYP0322 Case Reports/Case Series Actionable In a Phase I trial, JYP0322 treatment demonstrated safety and activity in patients with non-small cell lung cancer harboring ROS1 fusions and ROS1 G2032R, resulting in an objective response rate of 71.4% (5/7) (Cancer Res (2025) 85 (8_Supplement_2): CT052; NCT06128148). detail...
ROS1 fusion lung non-small cell carcinoma predicted - sensitive JYP0322 Phase I Actionable In a Phase I trial, JYP0322 treatment demonstrated safety and activity in patients with non-small cell lung cancer harboring ROS1 fusions, resulting in an objective response rate (ORR) of 85.7% (12/14) in ROS1-TKI naive patients and an ORR of 54.5% (12/22) in patients treated with at least 2 lines of systemic therapy and 1 line of a ROS1-TKI (Cancer Res (2025) 85 (8_Supplement_2): CT052; NCT06128148). detail...